PET Imaging Evaluation of [11C]SY08
NCT06098612
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The overall goal of the proposed research is to evaluate the use of [11C]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to evaluate the use of [11C]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls. The specific aims of the current study are: To determine brain uptake, distribution, and kinetics of [11C]SY08 in healthy individuals.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Parkinson's Disease
- Multiple System Atrophy
- Dementia With Lewy Bodies
- Healthy Controls
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Early Phase 1
- Ages
- 50 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Massachusetts General Hospital
- Last updated on ClinicalTrials.gov
- December 24, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- MGH · Charlestown, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.